Advanced heart failure in patients infected with human immunodeficiency virus

Is there equal access to care?

Nir Uriel, Nadav Nahumi, Paolo C. Colombo, Melana Yuzefpolskaya, Susan W. Restaino, Jason Han, Sunu S. Thomas, Arthur R. Garan, Hiroo Takayama, Donna M. Mancini, Yoshifumi Naka, Ulrich P. Jorde

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background Human immunodeficiency virus (HIV) infection has evolved from a highly stigmatized disease with certain progression to acquired immunodeficiency syndrome (AIDS) to a chronic disease affecting over 1 million Americans. With the success of current anti-retroviral therapies, cardiovascular disease, including advanced heart failure (HF), will be a major cause of morbidity and mortality in this population. Methods A survey concerning heart transplantation (HT) and left ventricular assist device (LVAD) implantation attitudes and outcomes in HIV-infected patients was distributed to 103 American and 9 Canadian HT centers via fax, e-mail or telephone. Results Eighty-nine centers (79%) responded. Eighteen HTs were performed in HIV+ patients with 1-, 2- and 5-year survival of 100%, 100% and 63%, respectively. Eighty-two centers (92%) have never performed HT in HIV+ patients and 51 centers (57%) marked HIV+ status as a contraindication. Rationales for contraindication included: (1) high-risk patients should be avoided given the scarcity of organ supply (59%); (2) immunosuppression required for HT may induce progression to AIDS (51%); and (3) drug interactions may worsen patients' clinical outcomes (49%). Thirty-five left ventricular assist device (LVAD) implantations in HIV+ patients were reported. Sixty-eight centers (76%) have never implanted an LVAD in an HIV+ patient and 21 centers (20%) marked HIV+ status as a contraindication, of which 61% indicated concern for device-related infection. Conclusions Most centers either explicitly consider HIV+ status as a contraindication for or have never treated HIV+ patients with advanced HF therapy. Our findings suggest unequal access to care and underscore the need to educate cardiovascular health-care providers on progress made with HIV therapies.

Original languageEnglish (US)
Pages (from-to)924-930
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume33
Issue number9
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Heart Failure
HIV
Heart Transplantation
Heart-Assist Devices
Acquired Immunodeficiency Syndrome
Telefacsimile
Postal Service
Virus Diseases
Drug Interactions
Telephone
Health Personnel
Immunosuppression
Chronic Disease
Cardiovascular Diseases
Therapeutics
Morbidity
Equipment and Supplies
Survival
Mortality
Infection

Keywords

  • contraindication
  • heart transplantation
  • human immunodeficiency virus
  • survey
  • ventricular assist device

ASJC Scopus subject areas

  • Transplantation
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery
  • Medicine(all)

Cite this

Advanced heart failure in patients infected with human immunodeficiency virus : Is there equal access to care? / Uriel, Nir; Nahumi, Nadav; Colombo, Paolo C.; Yuzefpolskaya, Melana; Restaino, Susan W.; Han, Jason; Thomas, Sunu S.; Garan, Arthur R.; Takayama, Hiroo; Mancini, Donna M.; Naka, Yoshifumi; Jorde, Ulrich P.

In: Journal of Heart and Lung Transplantation, Vol. 33, No. 9, 2014, p. 924-930.

Research output: Contribution to journalArticle

Uriel, N, Nahumi, N, Colombo, PC, Yuzefpolskaya, M, Restaino, SW, Han, J, Thomas, SS, Garan, AR, Takayama, H, Mancini, DM, Naka, Y & Jorde, UP 2014, 'Advanced heart failure in patients infected with human immunodeficiency virus: Is there equal access to care?', Journal of Heart and Lung Transplantation, vol. 33, no. 9, pp. 924-930. https://doi.org/10.1016/j.healun.2014.04.015
Uriel, Nir ; Nahumi, Nadav ; Colombo, Paolo C. ; Yuzefpolskaya, Melana ; Restaino, Susan W. ; Han, Jason ; Thomas, Sunu S. ; Garan, Arthur R. ; Takayama, Hiroo ; Mancini, Donna M. ; Naka, Yoshifumi ; Jorde, Ulrich P. / Advanced heart failure in patients infected with human immunodeficiency virus : Is there equal access to care?. In: Journal of Heart and Lung Transplantation. 2014 ; Vol. 33, No. 9. pp. 924-930.
@article{fb0241fa66c148ea86f6c15caf41689e,
title = "Advanced heart failure in patients infected with human immunodeficiency virus: Is there equal access to care?",
abstract = "Background Human immunodeficiency virus (HIV) infection has evolved from a highly stigmatized disease with certain progression to acquired immunodeficiency syndrome (AIDS) to a chronic disease affecting over 1 million Americans. With the success of current anti-retroviral therapies, cardiovascular disease, including advanced heart failure (HF), will be a major cause of morbidity and mortality in this population. Methods A survey concerning heart transplantation (HT) and left ventricular assist device (LVAD) implantation attitudes and outcomes in HIV-infected patients was distributed to 103 American and 9 Canadian HT centers via fax, e-mail or telephone. Results Eighty-nine centers (79{\%}) responded. Eighteen HTs were performed in HIV+ patients with 1-, 2- and 5-year survival of 100{\%}, 100{\%} and 63{\%}, respectively. Eighty-two centers (92{\%}) have never performed HT in HIV+ patients and 51 centers (57{\%}) marked HIV+ status as a contraindication. Rationales for contraindication included: (1) high-risk patients should be avoided given the scarcity of organ supply (59{\%}); (2) immunosuppression required for HT may induce progression to AIDS (51{\%}); and (3) drug interactions may worsen patients' clinical outcomes (49{\%}). Thirty-five left ventricular assist device (LVAD) implantations in HIV+ patients were reported. Sixty-eight centers (76{\%}) have never implanted an LVAD in an HIV+ patient and 21 centers (20{\%}) marked HIV+ status as a contraindication, of which 61{\%} indicated concern for device-related infection. Conclusions Most centers either explicitly consider HIV+ status as a contraindication for or have never treated HIV+ patients with advanced HF therapy. Our findings suggest unequal access to care and underscore the need to educate cardiovascular health-care providers on progress made with HIV therapies.",
keywords = "contraindication, heart transplantation, human immunodeficiency virus, survey, ventricular assist device",
author = "Nir Uriel and Nadav Nahumi and Colombo, {Paolo C.} and Melana Yuzefpolskaya and Restaino, {Susan W.} and Jason Han and Thomas, {Sunu S.} and Garan, {Arthur R.} and Hiroo Takayama and Mancini, {Donna M.} and Yoshifumi Naka and Jorde, {Ulrich P.}",
year = "2014",
doi = "10.1016/j.healun.2014.04.015",
language = "English (US)",
volume = "33",
pages = "924--930",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Advanced heart failure in patients infected with human immunodeficiency virus

T2 - Is there equal access to care?

AU - Uriel, Nir

AU - Nahumi, Nadav

AU - Colombo, Paolo C.

AU - Yuzefpolskaya, Melana

AU - Restaino, Susan W.

AU - Han, Jason

AU - Thomas, Sunu S.

AU - Garan, Arthur R.

AU - Takayama, Hiroo

AU - Mancini, Donna M.

AU - Naka, Yoshifumi

AU - Jorde, Ulrich P.

PY - 2014

Y1 - 2014

N2 - Background Human immunodeficiency virus (HIV) infection has evolved from a highly stigmatized disease with certain progression to acquired immunodeficiency syndrome (AIDS) to a chronic disease affecting over 1 million Americans. With the success of current anti-retroviral therapies, cardiovascular disease, including advanced heart failure (HF), will be a major cause of morbidity and mortality in this population. Methods A survey concerning heart transplantation (HT) and left ventricular assist device (LVAD) implantation attitudes and outcomes in HIV-infected patients was distributed to 103 American and 9 Canadian HT centers via fax, e-mail or telephone. Results Eighty-nine centers (79%) responded. Eighteen HTs were performed in HIV+ patients with 1-, 2- and 5-year survival of 100%, 100% and 63%, respectively. Eighty-two centers (92%) have never performed HT in HIV+ patients and 51 centers (57%) marked HIV+ status as a contraindication. Rationales for contraindication included: (1) high-risk patients should be avoided given the scarcity of organ supply (59%); (2) immunosuppression required for HT may induce progression to AIDS (51%); and (3) drug interactions may worsen patients' clinical outcomes (49%). Thirty-five left ventricular assist device (LVAD) implantations in HIV+ patients were reported. Sixty-eight centers (76%) have never implanted an LVAD in an HIV+ patient and 21 centers (20%) marked HIV+ status as a contraindication, of which 61% indicated concern for device-related infection. Conclusions Most centers either explicitly consider HIV+ status as a contraindication for or have never treated HIV+ patients with advanced HF therapy. Our findings suggest unequal access to care and underscore the need to educate cardiovascular health-care providers on progress made with HIV therapies.

AB - Background Human immunodeficiency virus (HIV) infection has evolved from a highly stigmatized disease with certain progression to acquired immunodeficiency syndrome (AIDS) to a chronic disease affecting over 1 million Americans. With the success of current anti-retroviral therapies, cardiovascular disease, including advanced heart failure (HF), will be a major cause of morbidity and mortality in this population. Methods A survey concerning heart transplantation (HT) and left ventricular assist device (LVAD) implantation attitudes and outcomes in HIV-infected patients was distributed to 103 American and 9 Canadian HT centers via fax, e-mail or telephone. Results Eighty-nine centers (79%) responded. Eighteen HTs were performed in HIV+ patients with 1-, 2- and 5-year survival of 100%, 100% and 63%, respectively. Eighty-two centers (92%) have never performed HT in HIV+ patients and 51 centers (57%) marked HIV+ status as a contraindication. Rationales for contraindication included: (1) high-risk patients should be avoided given the scarcity of organ supply (59%); (2) immunosuppression required for HT may induce progression to AIDS (51%); and (3) drug interactions may worsen patients' clinical outcomes (49%). Thirty-five left ventricular assist device (LVAD) implantations in HIV+ patients were reported. Sixty-eight centers (76%) have never implanted an LVAD in an HIV+ patient and 21 centers (20%) marked HIV+ status as a contraindication, of which 61% indicated concern for device-related infection. Conclusions Most centers either explicitly consider HIV+ status as a contraindication for or have never treated HIV+ patients with advanced HF therapy. Our findings suggest unequal access to care and underscore the need to educate cardiovascular health-care providers on progress made with HIV therapies.

KW - contraindication

KW - heart transplantation

KW - human immunodeficiency virus

KW - survey

KW - ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=84906077527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906077527&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2014.04.015

DO - 10.1016/j.healun.2014.04.015

M3 - Article

VL - 33

SP - 924

EP - 930

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 9

ER -